EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases

Mingcan Yu, Peng Chen, Ying Jin, Sheng Huang, Hao Jiang, Fulai Zhou, Mark L Chiu, Di Zhang iD

Cells · 2025

DOI: 10.3390/cells14221747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Mingcan Yu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tavotek Biotherapeutics Inc., 727 Norristown Road, Building 3, Suite 101, Ambler, PA 19002, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Cytokines, Inflammation, Hypersensitivity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thymic stromal lymphopoietin (TSLP) works synergistically with Th2 cytokines to regulate infection, inflammation, and metabolic homeostasis. However, their aberrant activities lead to the onset and sustaining of many types of allergic inflammatory diseases. While biologics drug molecules blocking either TSLP or IL-4/IL-13 show clinical efficacies, the broader effect of simultaneously targeting these cytokines remains to be explored. We generated a bispecific antibody (BsAb) targeting both TSLP and IL-4Rα, which effectively blocked the signaling cascades driven by TSLP, IL-4, and IL-13. The BsAb also neutralized TSLP-driven CD4+ T cell proliferation as well as IL-4 and IL-13-driven TF-1 cell proliferation. The BsAb reduced CCL17 release from CD14+ monocytes activated by LPS, TSLP, and IL-4 and reduced allergen-induced CCL26 and IL-5 release from co-cultures of PBMC, MRC-5, and A549 cells. In a TSLP/OVA-induced asthma model with transgenic human TSLP, TSLP receptor, IL-4, and IL-4Rα mice, the BsAb reduced every single allergic/inflammatory hallmark, while the single target blockade antibody failed to have such comprehensive effects. Our data suggested that simultaneous blocking of TSLP, IL-4, and IL-13 could offer broader control of allergic inflammation, which could translate to a more effective treatment of related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCytokinesInflammationHypersensitivityInterleukin-4 Receptor alpha SubunitAnimalsHumansThymic Stromal LymphopoietinMiceAsthmaFemaleInterleukin-4Mice, Inbred BALB CCell ProliferationInterleukin-13Signal Transduction

Stichwörter der Autor:innen

IL-13IL-4TSLPallergyantibodyantibody engineeringchronic inflammation

Substanzen

Antibodies, BispecificCytokinesThymic Stromal LymphopoietinInterleukin-4 Receptor alpha SubunitInterleukin-4Interleukin-13TSLP protein, human

Autor:innen und Institutionen

  • Tavotek Biotherapeutics Inc., 727 Norristown Road, Building 3, Suite 101, Ambler, PA 19002, USA.
  • Tavotek Biotherapeutics Inc., 999 Yinshanhu Road, Wuzhong District, Suzhou 215000, China.

ORCID-Profile: Di Zhang

Zitieren

APA

Yu, M., Chen, P., Jin, Y., Huang, S., Jiang, H., Zhou, F., Chiu, M. L., & Zhang, D. (2025). A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. Cells. https://doi.org/10.3390/cells14221747

Vancouver

Yu M, Chen P, Jin Y, Huang S, Jiang H, Zhou F, et al. A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases. Cells. 2025. doi:10.3390/cells14221747

BibTeX
@article{Yu2025,
  author = {Yu, Mingcan and Chen, Peng and Jin, Ying and Huang, Sheng and Jiang, Hao and Zhou, Fulai and Chiu, Mark L and Zhang, Di},
  title = {A Bispecific Antibody Blocking Both TSLP and IL-4Rα for the Treatment of Allergic Inflammatory Diseases},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14221747}
}
Kostenlos starten →